Genesis Biopharma, a biotechnology company developing targeted cancer therapies, has named Michael Handelman as chief financial officer (CFO), treasurer and secretary, succeeding Richard McKilligan.
Handelman currently serves as the CFO of Oxis International. Before joining Oxis, he served as CFO and chief operating officer (COO) of TechnoConcepts, a developing technology and manufacturing company. Prior to that, he was CFO of Interglobal Waste Management, a start-up manufacturing company. Handelman has also been CFO of the Los Angeles Kings, a National Hockey League franchise. He is a certified public accountant (CPA) and holds a degree in accounting from the City University of New York.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.